Use of D-enantiomeric Peptide Ligands of Monomeric polyQ-containing Proteins for the Therapy of Various Polyglutamine Diseases

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes the use of specific D-enantiomer peptide ligands that bind to monomeric polyglutamine (polyQ)-containing proteins for the treatment of various polyglutamine diseases. The invention covers peptides with particular amino acid sequences and their analogs, fragments, and derivatives for therapeutic applications.

Use CasesContent extracted from patent full text and abstract with AI.

• Therapeutic treatment of neurodegenerative diseases caused by polyglutamine protein aggregation, such as Huntington's disease, certain spinocerebellar ataxias, and other polyQ disorders
• Development of novel drugs targeting monomeric polyQ proteins to prevent disease progression
• Diagnostic tools for detecting the presence or levels of monomeric polyQ proteins in biological samples

BenefitsContent extracted from patent full text and abstract with AI.

• Potentially slows or halts the progression of polyglutamine diseases by targeting the underlying cause at the molecular level
• Utilizes D-enantiomer peptides, which are generally more resistant to degradation in the body, potentially leading to longer-lasting therapeutic effects
• Provides novel molecular tools for both treatment and diagnosis of devastating neurodegenerative disorders
• Could improve the quality of life and prognosis for patients affected by polyglutamine diseases

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

A peptide is described, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19, as well as homologs, fragments and parts thereof.